Amylin Pharmaceuticals Inc. (AMLN)

[surf1944]

1:54AM Amylin Pharma: Study finds BYETTA use was not associated with increased rate of acute pancreatitis vs other antidiabetic drugs (AMLN) 19.31 : Co and Eli Lilly (LLY) announce final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA injection was not increased compared to initiators of other antidiabetic therapies. The retrospective study used data accrued over three years from a large, geographically diverse U.S. healthcare insurance claims database to examine the risk of acute pancreatitis in more than 25,000 patients who were treated with BYETTA, relative to nearly 235,000 patients who were treated with other antidiabetes medications. Medical records from claims-identified cases of acute pancreatitis were reviewed by four gastroenterologists, blinded to drug exposure, using a standard assessment tool. In a nested case-control study based on the review, use of BYETTA was not associated with an increased rate of acute pancreatitis compared to the other antidiabetes medications, based on the adjusted odds ratio and 95% confidence interval for current, recent and past use of BYETTA.